To address advanced ovarian serous adenocarcinoma, T-cells were co-cultured with mesothelin antigen, anti-CD28, and recombinant human IL-2 to prepare αPD-1-meso CAR-T cells. This evidence concerns the gene MSLN and ovarian serous adenocarcinoma.